Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels

Authors

  • A. Sibille CHU de Liège-Hôpital du Sart Tilman, Liège, Belgium
  • M. Henket CHU de Liège-Hôpital du Sart Tilman, Liège, Belgium
  • J. L. Corhay CHU de Liège-Hôpital du Sart Tilman, Liège, Belgium
  • R. Louis CHU de Liège-Hôpital du Sart Tilman, Liège, Belgium
  • B. Duysinx CHU de Liège-Hôpital du Sart Tilman, Liège, Belgium

DOI:

https://doi.org/10.1080/0284186X.2019.1695063

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2020-03-03

How to Cite

Sibille, A., Henket, M., Corhay, J. L., Louis, R., & Duysinx, B. (2020). Clinical benefit to programmed death-1 inhibition for non-small-cell lung cancer is associated with higher blood eosinophil levels. Acta Oncologica, 59(3), 257–259. https://doi.org/10.1080/0284186X.2019.1695063

Issue

Vol. 59 No. 3 (2020): Acta Oncologica

Section

Articles